The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

BACKGROUND: To evaluate the short-term efficacy of intravitreal injections of aflibercept (IVA) to treat retinal angiomatous proliferation (RAP) and identify factors related to functional outcomes.

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading dose of a minimum of three monthly intravitreal aflibercept injections that ...